Therapeutic Class:Monoclonal Antibody Indications Bevastim is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of: Limitation of Use: Bevastim is not indicated for adjuvant treatment of colon cancer. Pharmacology Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) […]